{"id":"placebo-cyclophosphamide","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"5-20%","effect":"Hair loss"},{"rate":"5-20%","effect":"Infection"},{"rate":"5-20%","effect":"Bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, which prevents them from replicating and ultimately leads to cell death. This mechanism is particularly effective against rapidly dividing cells, such as those found in tumors.","oneSentence":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:52.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer, including lymphomas and leukemias"}]},"trialDetails":[{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT00433511","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-02","conditions":"Breast Adenocarcinoma","enrollment":4994},{"nctId":"NCT03295383","phase":"PHASE3","title":"Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2019-07-11","conditions":"Severe Forms of Mucous Membrane Pemphigoid","enrollment":130},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT06570811","phase":"PHASE2","title":"Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2024-08-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":40},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT04973137","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis","status":"TERMINATED","sponsor":"Prothena Biosciences Ltd.","startDate":"2021-08-30","conditions":"Light Chain (AL) Amyloidosis","enrollment":208},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT07183878","phase":"NA","title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08-20","conditions":"Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":138},{"nctId":"NCT06947967","phase":"PHASE3","title":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2025-08-12","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":224},{"nctId":"NCT03290456","phase":"NA","title":"Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-08-20","conditions":"Granulomatosis With Polyangitis","enrollment":146},{"nctId":"NCT01570764","phase":"PHASE3","title":"Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-01-14","conditions":"Systemic Sclerosis, Scleroderma, Interstitial Lung Disease","enrollment":40},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT06155331","phase":"PHASE2","title":"Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-12-01","conditions":"Breast Cancer Stage 2 and 3","enrollment":44},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT03314805","phase":"PHASE2","title":"PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"PhytoHealth Corporation","startDate":"2018-03-01","conditions":"Cancer-related Fatigue, Neutropenia, Malignant","enrollment":67},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT03267680","phase":"PHASE2","title":"IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-11-08","conditions":"Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion","enrollment":10},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT01363388","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-09","conditions":"Vasculitis","enrollment":67},{"nctId":"NCT02222155","phase":"PHASE2","title":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-04","conditions":"ANCA-associated Vasculitis","enrollment":42},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":12},{"nctId":"NCT01903330","phase":"PHASE2","title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2014-03","conditions":"Glioblastoma, Gliosarcoma","enrollment":84},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT03726879","phase":"PHASE3","title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-11","conditions":"Breast Cancer","enrollment":454},{"nctId":"NCT00719173","phase":"PHASE1","title":"Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-08","conditions":"Breast Cancer, Nausea and Vomiting","enrollment":19},{"nctId":"NCT03164993","phase":"PHASE2","title":"Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-06-01","conditions":"Cancer, Breast, Triple Negative Breast Cancer","enrollment":68},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT05239663","phase":"PHASE3","title":"GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-02-08","conditions":"Chemotherapy-Related Cognitive Impairment, Breast Cancer","enrollment":76},{"nctId":"NCT02897700","phase":"PHASE1","title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT06176339","phase":"PHASE2","title":"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2023-12-15","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT05234684","phase":"PHASE3","title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2022-11-02","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT03197935","phase":"PHASE3","title":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-24","conditions":"Triple-negative Breast Cancer","enrollment":333},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT03917797","phase":"PHASE2","title":"Mesenchymal Stromal Cells (MSC´s) in Renal Lupus","status":"UNKNOWN","sponsor":"Universidad de los Andes, Chile","startDate":"2019-04-02","conditions":"Lupus Erythematosus, Systemic, Lupus Glomerulonephritis","enrollment":39},{"nctId":"NCT03012100","phase":"PHASE2","title":"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-03-31","conditions":"Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":280},{"nctId":"NCT05432531","phase":"PHASE3","title":"Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-06-01","conditions":"Lupus Nephritis","enrollment":60},{"nctId":"NCT05595109","phase":"PHASE2, PHASE3","title":"Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-10-28","conditions":"Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities","enrollment":56},{"nctId":"NCT00976131","phase":"PHASE1","title":"Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2009-09","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT04044222","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-10-21","conditions":"Classic Hodgkin's Lymphoma","enrollment":240},{"nctId":"NCT05007444","phase":"PHASE2","title":"Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Tumor, Breast","enrollment":58},{"nctId":"NCT02460588","phase":"PHASE3","title":"Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":120},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT04036994","phase":"NA","title":"PBMT for the Management of CIA ( HAIRLASER )","status":"UNKNOWN","sponsor":"Hasselt University","startDate":"2020-06-17","conditions":"Breast Cancer, Chemotherapy-induced Alopecia, Alopecia","enrollment":30},{"nctId":"NCT02873819","phase":"PHASE2","title":"Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity","status":"COMPLETED","sponsor":"Gliknik Inc.","startDate":"2017-03-30","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":80},{"nctId":"NCT01777152","phase":"PHASE3","title":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2013-01-31","conditions":"Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma","enrollment":452},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT03908528","phase":"NA","title":"Alpha-Lipoic Acid in Breast Cancer Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-03-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":64},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT01632241","phase":"PHASE4","title":"Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2013-02-19","conditions":"Systemic Lupus Erythematosus","enrollment":503},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT02685059","phase":"PHASE2","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2016-06","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT02032277","phase":"PHASE3","title":"A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-02","conditions":"Triple Negative Breast Cancer","enrollment":634},{"nctId":"NCT03294577","phase":"PHASE3","title":"Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia","status":"UNKNOWN","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2019-10-23","conditions":"Chemotherapy-induced Neutropenia","enrollment":221},{"nctId":"NCT04620772","phase":"PHASE2, PHASE3","title":"Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2021-01-01","conditions":"Tuberculosis, Tubercular Meningitis, Arachnoiditis; Tuberculous (Etiology)","enrollment":40},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT01857232","phase":"PHASE2","title":"Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-10","conditions":"CINV","enrollment":342},{"nctId":"NCT04387630","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-06-05","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT01446809","phase":"NA","title":"Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-04","conditions":"Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma","enrollment":23},{"nctId":"NCT00002542","phase":"PHASE3","title":"Tamoxifen in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1993-07-20","conditions":"Breast Cancer","enrollment":672},{"nctId":"NCT04301739","phase":"PHASE3","title":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2020-04-17","conditions":"Triple Negative Breast Cancer","enrollment":522},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT01610869","phase":"PHASE2","title":"Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer","enrollment":117},{"nctId":"NCT03756090","phase":"NA","title":"The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-12-01","conditions":"Breast Cancer, Breast Diseases, Breast Neoplasms","enrollment":100},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT03654703","phase":"PHASE2","title":"Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML","status":"UNKNOWN","sponsor":"Capital Research Institute of Pediatrics","startDate":"2015-03-01","conditions":"Hematopoietic System--Cancer","enrollment":100},{"nctId":"NCT03576521","phase":"PHASE2","title":"Evaluation of Ocoxin®-Viusid® in Breast Cancer","status":"COMPLETED","sponsor":"Catalysis SL","startDate":"2015-05-13","conditions":"Breast Cancer, Breast Carcinoma, Adriamycin Toxicity","enrollment":120},{"nctId":"NCT01484496","phase":"PHASE3","title":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2011-11-16","conditions":"Systemic Lupus Erythematosus","enrollment":839},{"nctId":"NCT02451774","phase":"PHASE2, PHASE3","title":"Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction","status":"UNKNOWN","sponsor":"Ramón Óscar González-Ramella, Ph.D","startDate":"2015-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":44},{"nctId":"NCT03202446","phase":"PHASE3","title":"Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer","status":"TERMINATED","sponsor":"Eske Corporation S.A.C","startDate":"2016-06-13","conditions":"Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB, Breast Cancer Stage IV","enrollment":18},{"nctId":"NCT02692742","phase":"PHASE2","title":"Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia","status":"COMPLETED","sponsor":"Myelo Therapeutics GmbH","startDate":"2016-03","conditions":"Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer","enrollment":137},{"nctId":"NCT02049151","phase":"PHASE3","title":"Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":35},{"nctId":"NCT00486759","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-07-26","conditions":"B-cell Lymphoma","enrollment":787},{"nctId":"NCT01257802","phase":"PHASE3","title":"GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases","status":"TERMINATED","sponsor":"Joseph Mccune","startDate":"2011-05","conditions":"Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System","enrollment":14},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nacl"],"phase":"phase_3","status":"active","brandName":"Placebo-cyclophosphamide","genericName":"Placebo-cyclophosphamide","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death. Used for Treatment of various types of cancer, including lymphomas and leukemias.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}